We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

U.S. 503B COMPOUNDING PHARMACIES MARKET ANALYSIS

U.S. 503B Compounding Pharmacies Market, by Molecule (Acetaminophen, Phenylephrine, Midazolam, Esmolol, Vancomycin, Epinephrine, Adenocaine, Fentanyl/ Bupivacaine, Morphine, Amiodarone, Heparin, Ketamine, Dextrose, Hydromorphone, Bupivacaine, Lidocaine, BKK (Bupivacaine, ketorolac, Ketamine), RCK (Ropivacaine, Clonidine, Ketorolac), RKK (Ropivacaine, Ketorolac, Ketamine), Other Molecules), by Packaging Type (Vials, Pre-filled Syringes, Ampoule, Syringes, and Others)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • Published In : Aug 2022
  • Code : CMI4481
  • Pages :211
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:
  • Increasing product recalls
  • Risk associated with 503B compounding drugs

Market Restraint

Increasing product recalls is expected to hamper the growth of the U.S. 503B compounding pharmacies market. For instance, in August 2019, the U.S Food and Drug Administration request recall of sterile compounded drug products produced by Pacifico National Inc., an outsourcing facility doing business as AmEx pharmacy, in Melbourne, Florida. The drugs which included compounded ophthalmic products among other drug products cause unnecessary risks due to significant quality and sterility concerns.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.